Sequence information
DRAVP ID DRAVPc032
Name Odesivimab(REGN-3471)
Sequence Not available
Molecular Formula C6506H10024N1720O2030S42
Condition/Disease Zaire ebolavirus infection
Group Approved
Type Antibody
Description Odesivimab is part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. Odesivimab is indicated in combination with Maftivimab and Atoltivimab for the treatment of Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for Zaire ebolavirus infection. INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Maftivimab (REGN 3479), Odesivimab (REGN 3471), and Atoltivimab (REGN 3470) in equimolar proportions.INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.
Active sequence/Structure
External Links
DrugBank Accession Number DB15900
Pubchem ID 381608746
CHEMBL ID CHEMBL4298188
UNII UY9LQ8P6HW
CAS 2135632-30-1
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT03576690 | R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease | Ebolavirus Disease | Available | Not Available | Regeneron Pharmaceuticals |
| NCT05202288 | Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers | Ebolavirus Disease Prevention | Not yet recruiting | Phase 2 | ANRS, Emerging Infectious Diseases |
